ClinicalTrials.gg
RecruitingNCT06761560OPTIMAUpdated Aug 21, 2026

Optimizing Hydroxyurea Dosage With Pharmakokinetic in Patients Suffering of Moderate to Severe Sickle Cell Anemia

A Phase 2/3 interventional study of Pharmacokinetic based dosage change and Pharmacokinetic dosing in Sickle Cell Disease (SCD), sponsored by Yves Pastore. Recruiting at 1 site in Canada. Open to participants aged 6 Months to 18 Years. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Yves Pastore · Phase 2/3, Interventional, and Other

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
6 Months to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Anemia, Sickle Cell with a site in Canada — 15 open to participants now, 22 under way, 7 of them phase 3. Anemia, Sickle Cell · Canada.

Planned enrollment
44th of 49
29 · median 81
Started
2026
with 1 other
Phase 2/3
3 of 55
1 open now
Primary completion
2028-11
later than 14 of 21 live
Registered
52nd of 55
by date

Among the 55 studies in Anemia, Sickle Cell with a site in Canada, this one is the 44th largest by planned enrollment of the 49 interventional ones that give a count, is one of 2 that started in 2026, is one of 3 in phase 2/3, reaches primary completion later than 14 of the 21 other live ones, and was the 52nd registered.

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

15 of the 55 studies in Anemia, Sickle Cell with a site in Canada are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 6 Months to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Anemia, Sickle Cell with a site in Canada, or all of them as a file.
02

Study summary

The goal of this study is to evaluate if patients with sickle cell disease can achieve a maximum tolerate dose of hydroxuyrea (HU) over a period of 12 months faster with pharmacokinetic testing than the standard of care bloodwork follow-up. Pharmacokinetic test is used to evaluate the process by which drugs are absorbed, distributed in the body, localized in the tissues, and is excreted.

Patient will be a randomized (coin toss method) into 2 groups. Group A will have an increase of their HU dosage with pharmacokinetic results and Group B will have an increase of their HU dosage following the standard of care bloodwork follow-up.

Group C will include patient with sickle cell disease that has been taking HU for at least 12 months and will undergo a pharmacokinetic dosage to check the level of HU only one time.

03

Conditions studied

  • Sickle Cell Disease (SCD)

Browse trials for

Keywords

  • hydroxyurea
  • pharmacokinetic
  • sickle cell disease
04

Who can participate

Ages eligible
6 Months to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria (Group A and B) :

  • Have had confirmed diagnosis of SCD at CHU Sainte-Justine biochemistry lab with electrophoresis.
  • Patients with SS, SBThal0.
  • Agree to take hydroxyurea for a period of 12 months
  • Be between age of 6months old and 18 years old.
  • Have consented for participation in the study.

Inclusion Criteria (Group C) :

  • Have had confirmed diagnosis of SCD at CHU Sainte-Justine biochemistry lab with hemoglobin electrophoresis.
  • Patients with SS, SBThal0.
  • Have taken hydroxyurea for a period of at least 12 months, and have received HU at a stable dose and at MTD for at least 6 months.
  • Be between age of 6months old and 18 years old.
  • Have consented for participation in the study.

Exclusion Criteria:

  • Patients with sickle cell genotype other than SS or SBThal0 (SC, SBThal+, SE or SD)
  • Patients on chronic transfusion program
  • Patients have received a blood transfusion in the last 4 weeks of study enrollment.
  • Have received a hematopoietic stem-cell transplantation
  • Creatinine >2x normal for age
  • >2x normal for age
  • Sexually active females unwilling to comply with reliable method of
  • Pregnancy
  • Conditions which in the opinion of the investigator, would compromise participation in the study will be excluded.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
29 participants (estimated)

Study arms

  • Experimental
    Group A

    Patient starting hydroxyurea that will have PK sample procurements at different timpoints over a period of 12 months until HU-AUC shows MTD

    Diagnostic Test: Pharmacokinetic based dosage change

  • No intervention
    Group B

    Patient starting hydroxuyrea that will be followed as per standard of care over a period of 12 months until MTD has been reached

  • Experimental
    Group C

    Patient will undergo one PK sample procurement to evaluate level of HU-AUC after 12 months of taking hydroxyurea.

    Diagnostic Test: Pharmacokinetic dosing

Interventions

  • Diagnostic testPharmacokinetic based dosage change

    This study will compare 2 groups of sickle cell patients that are receiving hydroxyurea. Group A will have an increase in their dosage based on the pharmacokinetic result over a period of 12 months and Group B will have an increase in their dosage based on the standard of care follow-up over a period of 12 months. The aim is to evaluate if the group A can reach MTD faster than than the Group B

  • Diagnostic testPharmacokinetic dosing

    Patient with sickle cell disease will undergo one pharmacokinetic test after taking 12 months of hydroxyurea to evaluate HU-AUC at that timepoint

06

What researchers measure

Primary outcomes

  1. Evaluation of HU-PK at 6 months between group A and group B

    Pharmakocinetic dosage of hydroxyurea will be determined at 6 months in group A and group B. The investigator hypothesize that HU-PK in group B may be lower (suboptimal) compared to group A.

    Time frame: At 6 months

Secondary outcomes

  1. Time to reach maximal tolerated dose (MTD)

    Time (weeks) to achieve MTD in groups A and B will be determined by evaluating the % of patients reaching MTD (at 3 , 6, 9 and 12 months) in each group. MTD is defined by hematological parameters: Absolute neutrophile count 0.8-1.5x10\*9/L or platelet 80-120x10\*9/L or absolute reticulocyte count 50-80x10\*9/L)

    Time frame: 3, 6, 9 and 12 months

  2. Fetal hemoglobin

    Comparing fetal hemoglobin between group A and B

    Time frame: at 3, 6 and 12 months

  3. Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) in group A and B

    Evaluation of the incidence adverse events (AE) and serious adverse events (SAE) in both groups

    Time frame: From enrollment to 12 months

  4. Evaluation of % of patients reaching AUC of 115 +/- 15mg*h/L at 12 months compared to the percentage of patients in group C reaching the same AUC

    Percentage of patients in the HU-AUC (group A) with an AUC of 115 mg\*h/L at 12 months will be compared to the percentage of patients in group C with an AUC of 115 +/-15 mg\*h/L.

    Time frame: At 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Verduzco LA, Nathan DG. Sickle cell disease and stroke. Blood. 2009 Dec 10;114(25):5117-25. doi: 10.1182/blood-2009-05-220921. PubMed 19797523 ↗
  • Meier ER. Treatment Options for Sickle Cell Disease. Pediatr Clin North Am. 2018 Jun;65(3):427-443. doi: 10.1016/j.pcl.2018.01.005. PubMed 29803275 ↗
  • McGann PT, Niss O, Dong M, Marahatta A, Howard TA, Mizuno T, Lane A, Kalfa TA, Malik P, Quinn CT, Ware RE, Vinks AA. Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia. Am J Hematol. 2019 Aug;94(8):871-879. doi: 10.1002/ajh.25510. Epub 2019 Jun 12. PubMed 31106898 ↗
  • Dong M, McGann PT. Changing the Clinical Paradigm of Hydroxyurea Treatment for Sickle Cell Anemia Through Precision Medicine. Clin Pharmacol Ther. 2021 Jan;109(1):73-81. doi: 10.1002/cpt.2028. Epub 2020 Oct 8. PubMed 32869281 ↗
  • Marahatta A, Ware RE. Hydroxyurea: Analytical techniques and quantitative analysis. Blood Cells Mol Dis. 2017 Sep;67:135-142. doi: 10.1016/j.bcmd.2017.08.009. Epub 2017 Aug 8. PubMed 28847416 ↗
  • Hai X, Guo M, Gao C, Zhou J. Quantification of hydroxyurea in human plasma by HPLC-MS/MS and its application to pharmacokinetics in patients with chronic myeloid leukaemia. J Pharm Biomed Anal. 2017 Apr 15;137:213-219. doi: 10.1016/j.jpba.2017.01.008. Epub 2017 Jan 10. PubMed 28131939 ↗
  • Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, Rana S, Thornburg CD, Rogers ZR, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik SA, Howard TH, Wynn LW, Kutlar A, Armstrong FD, Files BA, Goldsmith JC, Waclawiw MA, Huang X, Thompson BW; BABY HUG investigators. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011 May 14;377(9778):1663-72. doi: 10.1016/S0140-6736(11)60355-3. PubMed 21571150 ↗
  • Thornburg CD, Files BA, Luo Z, Miller ST, Kalpatthi R, Iyer R, Seaman P, Lebensburger J, Alvarez O, Thompson B, Ware RE, Wang WC; BABY HUG Investigators. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood. 2012 Nov 22;120(22):4304-10; quiz 4448. doi: 10.1182/blood-2012-03-419879. Epub 2012 Aug 22. PubMed 22915643 ↗
  • Yahouedehou SCMA, Adorno EV, da Guarda CC, Ndidi US, Carvalho SP, Santiago RP, Aleluia MM, de Oliveira RM, Goncalves MS. Hydroxyurea in the management of sickle cell disease: pharmacogenomics and enzymatic metabolism. Pharmacogenomics J. 2018 Dec;18(6):730-739. doi: 10.1038/s41397-018-0045-1. Epub 2018 Sep 12. PubMed 30206297 ↗
  • Switzer JA, Hess DC, Nichols FT, Adams RJ. Pathophysiology and treatment of stroke in sickle-cell disease: present and future. Lancet Neurol. 2006 Jun;5(6):501-12. doi: 10.1016/S1474-4422(06)70469-0. PubMed 16713922 ↗
  • Quinn CT. Sickle cell disease in childhood: from newborn screening through transition to adult medical care. Pediatr Clin North Am. 2013 Dec;60(6):1363-81. doi: 10.1016/j.pcl.2013.09.006. PubMed 24237976 ↗
  • Hebbel RP. Ischemia-reperfusion injury in sickle cell anemia: relationship to acute chest syndrome, endothelial dysfunction, arterial vasculopathy, and inflammatory pain. Hematol Oncol Clin North Am. 2014 Apr;28(2):181-98. doi: 10.1016/j.hoc.2013.11.005. PubMed 24589261 ↗
  • Kuypers FA. Hemoglobin s polymerization and red cell membrane changes. Hematol Oncol Clin North Am. 2014 Apr;28(2):155-79. doi: 10.1016/j.hoc.2013.12.002. Epub 2014 Jan 22. PubMed 24589260 ↗
  • Pleasants S. Epidemiology: a moving target. Nature. 2014 Nov 13;515(7526):S2-3. doi: 10.1038/515S2a. No abstract available. PubMed 25390139 ↗

Related links

Individual participant data

Plan to share: No — This is a pilot study with a small group of participant.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Nov 2028, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2024
First posted
Jan 7, 2025
StartActual
Feb 3, 2026
Primary completionEst.
Nov 25, 2028
CompletionEst.
Nov 25, 2028
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06761560
Lead sponsor
Yves Pastore
Responsible party
Yves Pastore (Co-director Sickle Cell Programm, Principal Investigator, St. Justine's Hospital) — Sponsor-investigator
First posted
Jan 7, 2025
Start date
Feb 3, 2026
Primary completion
Nov 25, 2028 (estimated)
Completion
Nov 25, 2028 (estimated)
Last update
Aug 21, 2026

Study contacts

Yves Pastore, MD
Contact
yves.pastore.med@ssss.gouv.qc.ca
514-345-4931 ext. 5027
Bianka Courcelle, Research nurse, RN
Contact
bianka.courcelle.hsj@ssss.gouv.qc.ca
514-345-4931 ext. 3757

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion